The purpose of this study is to determine the safety and tolerability of STA-5326 given once daily or twice daily to Crohn's Disease patients with moderate disease.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
48
Advanced Clinical Therapeutics
Tucson, Arizona, United States
Advanced Clinical Research Institute
Anaheim, California, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Venture Research Institute, LLC
North Miami Beach, Florida, United States
Shafran Gastoenterology Center
Winter Park, Florida, United States
Northwestern University
Chicago, Illinois, United States
University of Chicago
Chicago, Illinois, United States
Heart of America Research Institute
Topeka, Kansas, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Boston Medical Center
Boston, Massachusetts, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
...and 8 more locations